Biomaterial Database

Sequential antimicrobial therapy: pharmacokinetic and pharmacodynamic considerations in sequential therapy. 1998

A P MacGowan, and K E Bowker

Bristol Centre for Antimicrobial Research & Evaluation, Southmead Health Services NHS Trust and University of Bristol, Westbury-on-Trym, UK.

The pharmacodynamic factors important in sequential therapy are largely unknown. This is because most pharmacodynamic investigations concentrate on how bacterial populations respond to first antimicrobial exposures. However, it is likely that for B lactams T>MIC and for quinolones the antimicrobial AUC/MIC ratio will be important. Factors which reduce antimicrobial absorption will impact on these parameters and require further study.

UI	MeSH Term	Description	Entries
D010406	Penicillins	A group of antibiotics that contain 6-aminopenicillanic acid with a side chain attached to the 6-amino group. The penicillin nucleus is the chief structural requirement for biological activity. The side-chain structure determines many of the antibacterial and pharmacological characteristics. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1065)	Antibiotics, Penicillin,Penicillin,Penicillin Antibiotics
D002511	Cephalosporins	A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid.	Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D000284	Administration, Oral	The giving of drugs, chemicals, or other substances by mouth.	Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000890	Anti-Infective Agents	Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection.	Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D000900	Anti-Bacterial Agents	Substances that inhibit the growth or reproduction of BACTERIA.	Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D042462	4-Quinolones	QUINOLONES containing a 4-oxo (a carbonyl in the para position to the nitrogen). They inhibit the A subunit of DNA GYRASE and are used as antimicrobials. Second generation 4-quinolones are also substituted with a 1-piperazinyl group at the 7-position and a fluorine at the 6-position.	4-Oxoquinoline,4-Quinolinone,4-Quinolone,4-Oxoquinolines,4-Quinolinones,4 Oxoquinoline,4 Oxoquinolines,4 Quinolinone,4 Quinolinones,4 Quinolone,4 Quinolones

Related Publications

A P MacGowan, and K E Bowker

Pharmacokinetic and pharmacodynamic considerations in antimicrobial therapy for sepsis.

May 2020, Expert opinion on drug metabolism & toxicology,

A P MacGowan, and K E Bowker

Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations.

January 2003, Clinical pharmacokinetics,

A P MacGowan, and K E Bowker

Pharmacokinetic and pharmacodynamic considerations in gene therapy.

November 2003, Drug discovery today,

A P MacGowan, and K E Bowker

Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.

October 2013, Clinical pharmacokinetics,

A P MacGowan, and K E Bowker

Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin.

January 2001, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,

A P MacGowan, and K E Bowker

Pharmacokinetic and pharmacodynamic considerations of antimicrobial drug therapy in cancer patients with kidney dysfunction.

July 2015, World journal of nephrology,

A P MacGowan, and K E Bowker

Pharmacokinetic and pharmacodynamic implications in inhalable antimicrobial therapy.

May 2015, Advanced drug delivery reviews,

A P MacGowan, and K E Bowker

Cigarettes and drug therapy: pharmacokinetic and pharmacodynamic considerations.

February 1990, Clinical pharmacy,

A P MacGowan, and K E Bowker

The importance of appropriate antimicrobial dosing: pharmacokinetic and pharmacodynamic considerations.

September 2004, The Annals of pharmacotherapy,